Gao takes chair from Chan at China Biologic
This article was originally published in Scrip
Executive Summary
David (Xiaoying) Gao has been elected chairman of the board of directors at China Biologic Products, taking over from Siu Ling Chan who served for more than five years, and who will remain on the board. Mr Gao’s appointment comes as the board adopts a series of measures to improve the company’s corporate governance, enhancing the independence and transparency of the board. These include increasing the size of the board from seven to nine members, with the intention of appointing two new independent directors. Mr Gao joined the board of directors in October 2011. China Biologic operates through subsidiaries in China as a major plasma-based biopharmaceutical company in that market. Mr Gao was previously CEO and director of BMP Sunstone, which was acquired by Sanofi last year. He was also chairman of Beijing Med-Pharm from 2002 to 2004. The company has also appointed Ming Yang as vice-president, finance and compliance and treasurer.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.